Home › Research › Drug development
The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance
Rose RV, Kass JS.. Continuum (Minneapolis, Minn.), 2022-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract This article addresses the potential legal ramifications for neurologists caring for patients with Alzheimer disease (AD) who elect neither to prescribe aducanumab nor to refer patients with AD for treatment with aducanumab. To prevail against a neurologist for failing to prescribe aducanumab or refer for aducanumab treatment, the plaintiff would have to establish that the neurologist's failure to prescribe the medication or refer for treatment was a breach of the standard of care. The standard of care is conceptualized as the generally accepted approach to diagnosing or treating a condition.
What this study adds
Evidence grade: Low
This article addresses the potential legal ramifications for neurologists who elect neither to prescribe aducanumab nor to refer patients with Alzheimer disease for treatment with it. It notes that to prevail, a plaintiff would have to establish that the failure to prescribe or refer was a breach of the standard of care, and that controversy surrounds the FDA's approval process for aducanumab.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rose, R. V., & Kass, J. S. (2022). The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance. Continuum (Minneapolis, Minn.). https://doi.org/10.1212/con.0000000000001164
Vancouver
Rose RV, Kass JS. The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance. Continuum (Minneapolis, Minn.). 2022. doi:10.1212/con.0000000000001164. PMID: 35678410.
BibTeX
@article{rose2022-35678410,
author = {Rose, R. V. and Kass, J. S.},
title = {{The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance}},
journal = {Continuum (Minneapolis, Minn.)},
year = {2022},
doi = {10.1212/con.0000000000001164},
pmid = {35678410},
url = {https://doi.org/10.1212/con.0000000000001164}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- To prevail against a neurologist for failing to prescribe aducanumab or refer for aducanumab treatment, the plaintiff would have to establish that the neurologist's failure to prescribe the medication or refer for treatment was a breach of the standard of care.
- The standard of care is conceptualized as the generally accepted approach to diagnosing or treating a condition.
- However, the controversy surrounding the US Food and Drug Administration's (FDA's) approval process for aducanumab (which was based on the drug's efficacy at reducing brain amyloidosis rather than on clinically meaningful efficacy) as well as the American Academy of Neurology (AAN) position statement on aducanumab and the recent decision by the Centers for Medicare & Medicaid Services (CMS) to limit Medicare coverage of the drug and its associated costs to patients enrolled in qualifying clinical trials indicate that aducanumab cannot yet be considered the standard of care for the treatment of AD.
- Although deciding not to prescribe aducanumab does not violate the standard of care, neurologists treating patients with AD and not recommending this treatment should explain to their patients and their patients' surrogate decision makers why they are not recommending the treatment.
Why it matters
This article addresses the potential legal ramifications for neurologists who elect neither to prescribe aducanumab nor to refer patients with Alzheimer disease for treatment with it. It notes that to prevail, a plaintiff would have to establish that the failure to prescribe or refer was a breach of the standard of care, and that controversy surrounds the FDA's approval process for aducanumab.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Continuum (Minneapolis, Minn.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Joseph S. Kass: h-index 28 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35678410) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also in Drug development
107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.